Cargando…
Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
Roughly one third of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitive mutated (EGFRm) tumors experience disease progression through central nervous system (CNS) metastases during treatment. Although EGFR-TKIs have been r...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497791/ https://www.ncbi.nlm.nih.gov/pubmed/34630120 http://dx.doi.org/10.3389/fphar.2021.750031 |
_version_ | 1784580030883430400 |
---|---|
author | Zhang, Yuhan Zhang, Yaoshuai Niu, Wenwen Ge, Xianming Huang, Fuhao Pang, Jinlong Li, Xian Wang, Yu Gao, Wei Fan, Fangtian Li, Shanshan Liu, Hao |
author_facet | Zhang, Yuhan Zhang, Yaoshuai Niu, Wenwen Ge, Xianming Huang, Fuhao Pang, Jinlong Li, Xian Wang, Yu Gao, Wei Fan, Fangtian Li, Shanshan Liu, Hao |
author_sort | Zhang, Yuhan |
collection | PubMed |
description | Roughly one third of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitive mutated (EGFRm) tumors experience disease progression through central nervous system (CNS) metastases during treatment. Although EGFR-TKIs have been reported to be favored in some patients with EGFRm NSCLC CNS metastases, novel EGFR-TKIs with proven efficacy in CNS pathologies are clinically needed.To investigate whether almonertinib, a novel third-generation EGFR-TKI for NSCLC, can cross the blood-brain barrier (BBB) and deliver treatment for EGFR-mutant NSCLC brain metastases and spinal cord metastases, we constructed NSCLC brain metastasis and spinal cord metastasis models in vivo to observe the anti-tumor effects of almonertinib. Using ABCB1-MDCK and BCRP-MDCK monolayer cells as the in vitro study model, the effects of transport time and drug concentration on the apparent permeability coefficient of almonertinib and its active metabolite, HAS-719, were investigated. The results of this study show that almonertinib can significantly inhibit PC9 brain and spinal cord metastases. Pharmacokinetic studies in mice revealed that almonertinib has good BBB penetration ability, whereas the metabolite HAS-719 does not easily penetrate the BBB. Early clinical evidence of almonertinib activity in patients with EGFRm-advanced NSCLC and brain metastases has also been reported. In conclusion, almonertinib easily penetrates the BBB and inhibits advanced NSCLC brain and spinal cord metastases. |
format | Online Article Text |
id | pubmed-8497791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84977912021-10-09 Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models Zhang, Yuhan Zhang, Yaoshuai Niu, Wenwen Ge, Xianming Huang, Fuhao Pang, Jinlong Li, Xian Wang, Yu Gao, Wei Fan, Fangtian Li, Shanshan Liu, Hao Front Pharmacol Pharmacology Roughly one third of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitive mutated (EGFRm) tumors experience disease progression through central nervous system (CNS) metastases during treatment. Although EGFR-TKIs have been reported to be favored in some patients with EGFRm NSCLC CNS metastases, novel EGFR-TKIs with proven efficacy in CNS pathologies are clinically needed.To investigate whether almonertinib, a novel third-generation EGFR-TKI for NSCLC, can cross the blood-brain barrier (BBB) and deliver treatment for EGFR-mutant NSCLC brain metastases and spinal cord metastases, we constructed NSCLC brain metastasis and spinal cord metastasis models in vivo to observe the anti-tumor effects of almonertinib. Using ABCB1-MDCK and BCRP-MDCK monolayer cells as the in vitro study model, the effects of transport time and drug concentration on the apparent permeability coefficient of almonertinib and its active metabolite, HAS-719, were investigated. The results of this study show that almonertinib can significantly inhibit PC9 brain and spinal cord metastases. Pharmacokinetic studies in mice revealed that almonertinib has good BBB penetration ability, whereas the metabolite HAS-719 does not easily penetrate the BBB. Early clinical evidence of almonertinib activity in patients with EGFRm-advanced NSCLC and brain metastases has also been reported. In conclusion, almonertinib easily penetrates the BBB and inhibits advanced NSCLC brain and spinal cord metastases. Frontiers Media S.A. 2021-09-24 /pmc/articles/PMC8497791/ /pubmed/34630120 http://dx.doi.org/10.3389/fphar.2021.750031 Text en Copyright © 2021 Zhang, Zhang, Niu, Ge, Huang, Pang, Li, Wang, Gao, Fan, Li and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Yuhan Zhang, Yaoshuai Niu, Wenwen Ge, Xianming Huang, Fuhao Pang, Jinlong Li, Xian Wang, Yu Gao, Wei Fan, Fangtian Li, Shanshan Liu, Hao Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models |
title | Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models |
title_full | Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models |
title_fullStr | Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models |
title_full_unstemmed | Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models |
title_short | Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models |
title_sort | experimental study of almonertinib crossing the blood-brain barrier in egfr-mutant nsclc brain metastasis and spinal cord metastasis models |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497791/ https://www.ncbi.nlm.nih.gov/pubmed/34630120 http://dx.doi.org/10.3389/fphar.2021.750031 |
work_keys_str_mv | AT zhangyuhan experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT zhangyaoshuai experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT niuwenwen experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT gexianming experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT huangfuhao experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT pangjinlong experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT lixian experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT wangyu experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT gaowei experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT fanfangtian experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT lishanshan experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels AT liuhao experimentalstudyofalmonertinibcrossingthebloodbrainbarrierinegfrmutantnsclcbrainmetastasisandspinalcordmetastasismodels |